Marrone Bio Innovations (NASDAQ:MBII) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a note issued to investors on Thursday.
According to Zacks, “Marrone Bio Innovations Inc. develops environmentally safe bio-based products. The Company specializes in the discovery, development, and marketing of natural products for weed, pest, water resource, and plant disease management. It offers crop protection products for conventional and organic crop production, including herbicides for weed control, fungicides for plant disease control, nematicides for parasitic roundworm control, insecticides for insect and mite killers and plant growth regulators that growers use to increase crop yields, enhance plant health, manage pest resistance, and reduce chemical residues. Marrone Bio Innovations Inc. is headquartered in Davis, California. “
MBII has been the subject of several other reports. ValuEngine raised shares of Marrone Bio Innovations from a “strong sell” rating to a “sell” rating in a research note on Friday, February 2nd. HC Wainwright set a $4.00 price objective on shares of Marrone Bio Innovations and gave the company a “buy” rating in a research note on Thursday, December 21st. Two analysts have rated the stock with a sell rating, two have assigned a hold rating and one has issued a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus price target of $2.50.
Marrone Bio Innovations (MBII) opened at $1.23 on Thursday. The company has a debt-to-equity ratio of -1.14, a quick ratio of 0.36 and a current ratio of 0.69. Marrone Bio Innovations has a one year low of $0.85 and a one year high of $2.30.
In other news, insider Ardsley Advisory Partners acquired 6,666,667 shares of the stock in a transaction dated Monday, February 5th. The stock was purchased at an average cost of $0.75 per share, with a total value of $5,000,000.25. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 2.80% of the company’s stock.
TRADEMARK VIOLATION WARNING: “Zacks Investment Research Downgrades Marrone Bio Innovations (MBII) to Sell” was first published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this news story on another publication, it was copied illegally and reposted in violation of United States & international copyright and trademark laws. The legal version of this news story can be viewed at https://www.dispatchtribunal.com/2018/02/17/zacks-investment-research-downgrades-marrone-bio-innovations-mbii-to-sell.html.
About Marrone Bio Innovations
Marrone Bio Innovations, Inc offers bio-based pest management and plant health products. The Company’s bio-based products include naturally occurring microorganisms, such as bacteria, fungi and plant extracts. It sells its products to crop protection market. Its four crop protection products include Regalia, Grandevo, Venerate and Majestene.
Receive News & Ratings for Marrone Bio Innovations Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marrone Bio Innovations and related companies with MarketBeat.com's FREE daily email newsletter.